Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production.
暂无分享,去创建一个
A. Sher | C. Serhan | J. Aliberti | F. Machado | C. Scanga | A. Báfica | Sandra White
[1] M. Arnaout,et al. A synthetic eicosanoid LX‐mimetic unravels host‐donor interactions in allogeneic BMT‐induced GvHD to reveal an early protective role for host neutrophils , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] J. Aliberti. Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma GONDII , 2005, Nature Reviews Immunology.
[3] C. Serhan,et al. Lipoxins and novel 15‐epi‐lipoxin analogs display potent anti‐inflammatory actions after oral administration , 2004, British journal of pharmacology.
[4] A. Sher,et al. MyD88-Deficient Mice Display a Profound Loss in Resistance to Mycobacterium tuberculosis Associated with Partially Impaired Th1 Cytokine and Nitric Oxide Synthase 2 Expression , 2004, Infection and Immunity.
[5] A. Sher,et al. Exogenous Pathogen and Plant 15-Lipoxygenase Initiate Endogenous Lipoxin A4 Biosynthesis , 2004, The Journal of experimental medicine.
[6] A. Goldfeld. Genetic susceptibility to pulmonary tuberculosis in Cambodia. , 2004, Tuberculosis.
[7] O. Levy,et al. Expression of BPI (bactericidal/permeability-increasing protein) in human mucosal epithelia. , 2003, Biochemical Society transactions.
[8] Yu-Jin Jung,et al. Increased interleukin‐10 expression is not responsible for failure of T helper 1 immunity to resolve airborne Mycobacterium tuberculosis infection in mice , 2003, Immunology.
[9] A. Sher,et al. Parasite-induced Lipoxin A4 Is an Endogenous Regulator of IL-12 Production and Immunopathology in Toxoplasma gondii Infection , 2002, The Journal of experimental medicine.
[10] Yu-Jin Jung,et al. Evidence Inconsistent with a Negative Influence of T Helper 2 Cells on Protection Afforded by a Dominant T Helper 1 Response against Mycobacterium tuberculosis Lung Infection in Mice , 2002, Infection and Immunity.
[11] C. Serhan. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. , 2002, Prostaglandins & other lipid mediators.
[12] O. Levy,et al. Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[13] A. Sher,et al. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity , 2002, Nature Immunology.
[14] D. Rennick,et al. Endogenous Inhibition of Antimycobacterial Immunity by IL‐10 Varies between Mycobacterial Species , 2001, Scandinavian journal of immunology.
[15] J. Keane,et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.
[16] C. Serhan,et al. Cutting Edge: Lipoxin (LX) A4 and Aspirin-Triggered 15-Epi-LXA4 Block Allergen-Induced Eosinophil Trafficking1 , 2000, The Journal of Immunology.
[17] G. Dai,et al. Effects of modulating TGF-beta 1 on immune responses to mycobacterial infection in guinea pigs. , 1999, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[18] C. Clish,et al. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo , 1999 .
[19] C. Serhan,et al. Lipoxin (LX)A4 and Aspirin-triggered 15-epi-LXA4 Inhibit Tumor Necrosis Factor 1α–initiated Neutrophil Responses and Trafficking: Regulators of a Cytokine–Chemokine Axis , 1999, The Journal of experimental medicine.
[20] F. Deist,et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. , 1998, Science.
[21] J. Casanova,et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. , 1998, Science.
[22] L. Dubé,et al. A Randomized Controlled Trial Comparing Zileuton With Theophylline in Moderate Asthma , 1998 .
[23] J. Mudgett,et al. Identification of nitric oxide synthase as a protective locus against tuberculosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[24] L. Dubé,et al. Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group. , 1997, The American journal of managed care.
[25] M. Newport,et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. , 1996, The New England journal of medicine.
[26] E. Israel,et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. , 1996, JAMA.
[27] J. Flynn,et al. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. , 1995, Journal of immunology.
[28] C. Lowenstein,et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. , 1995, Immunity.
[29] Alan D. Roberts,et al. The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. , 1995, Immunology.
[30] C. Serhan,et al. Action of novel eicosanoids lipoxin A and B on human natural killer cell cytotoxicity: effects on intracellular cAMP and target cell binding. , 1985, Journal of immunology.